Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including ...
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Conditions
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 582
- Registration Number
- NCT05489211
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
PT886 for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Phanes Therapeutics
- Target Recruit Count
- 135
- Registration Number
- NCT05482893
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Sarah Cannon Research Institute (SCRI), Denver, Colorado, United States
🇺🇸Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2023-02-28
- Target Recruit Count
- 18
- Registration Number
- NCT05480280
- Locations
- 🇨🇳
Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
- Conditions
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-07-21
- Target Recruit Count
- 17
- Registration Number
- NCT05469061
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for LA-NPC
- Conditions
- Interventions
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 172
- Registration Number
- NCT05433597
SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 25
- Registration Number
- NCT05412082
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
A Study to Compare Onivyde Manufactured at Two Different Production Sites in Adult Participants With Advanced Cancer in the Pancreas
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 177
- Registration Number
- NCT05383352
- Locations
- 🇫🇷
Institut BERGONIE Centre de Lutte Contre le Cancer, Bordeaux, France
🇦🇺Flinders Medical Centre, Bedford Park, Australia
🇦🇺Peninsula and Southeast Oncology - Frankston Private Hospital, Frankston, Australia
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Akeso
- Target Recruit Count
- 104
- Registration Number
- NCT05382442
- Locations
- 🇨🇳
The Sixth Hospital,Sun Yat-sen University, Guanzhou, Guangdong, China
A Study of ASP3082 in Adults With Advanced Solid Tumors
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 541
- Registration Number
- NCT05382559
- Locations
- 🇺🇸
Florida Cancer Specialist, Lake Mary, Florida, United States
🇺🇸Case Western, Cleveland, Ohio, United States
🇺🇸University of Wisconsin Hospital, Madison, Wisconsin, United States
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 225
- Registration Number
- NCT05379595
- Locations
- 🇺🇸
O Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸University of California, Los Angeles UCLA, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.